default author photo

Toshimi Takano

Toranomon Hospital - Department of Medical Oncology

Tokyo, 105-8470

Japan

SCHOLARLY PAPERS

3

DOWNLOADS

299

TOTAL CITATIONS

0

Scholarly Papers (3)

1.

CYP2D6 Genotype-Guided Tamoxifen Dosing in Hormone Receptor-Positive Metastatic Breast Cancer (TARGET-1): A Randomized, Open-Label, Phase 2 Study

Number of pages: 35 Posted: 06 Apr 2019
National Cancer Center Hospital - Department of Breast and Medical Oncology, Keio University - Department of Clinical Pharmacokinetics and Pharmacodynamics, Toranomon Hospital - Department of Medical Oncology, Fukushima Medical University, Yokohama City University, National Cancer Center Hospital - Department of Breast and Medical Oncology, National Hospital Organization Hokkaido Cancer Center - Department of Breast Surgery, Showa University - Advanced Cancer Translational Research Institute, Kumamoto Shinto General Hospital, Tokyo-West Tokushukai Hospital, Seirei Sakura Citizen Hospital, University of Texas at Houston - MD Anderson Cancer Center, RIKEN Center for Integrative Medical Sciences, RIKEN Center for Integrative Medical Sciences, National Cancer Center Hospital - Department of Breast and Medical Oncology and Keio University - Department of Clinical Pharmacokinetics and Pharmacodynamics
Downloads 147 (502,974)

Abstract:

Loading...

breast cancer, CYP2D6, endoxifen, genotype-guided dosing, tamoxifen

2.

Phase 2 Study of Nivolumab Plus Bevacizumab Plus Paclitaxel in Patients with HER2-Negative Metastatic Breast Cancer

Number of pages: 34 Posted: 04 May 2021
Toranomon Hospital - Department of Medical Oncology, Showa University - Advanced Cancer Translational Research Institute, National Cancer Center Hospital East - Department of Breast and Medical Oncology, Kindai University - Department of Medical Oncology, National Hospital Organization Hokkaido Cancer Center - Department of Breast Surgery, Toranomon Hospital - Department of Medical Oncology, Toranomon Hospital - Department of Breast and Endocrine Surgery, Nagoya University - Graduate School of Medicine, Gifu University - Department of Surgical Oncology, Kobe University - Medical Oncology/Hematology, Hyogo Cancer Center - Department of Medical Oncology, Hiroshima University Hospital - Center for Integrated Medical Research, National Cancer Center Hospital - Department of Experimental Therapeutics and Toranomon Hospital - Department of Medical Oncology
Downloads 106 (659,652)

Abstract:

Loading...

3.

Safety and Efficacy of Nivolumab Plus Bevacizumab, Paclitaxel for HER2-Negative Metastatic Breast Cancer: Primary Result and Biomarker Data of a Phase 2 Trial

Number of pages: 51 Posted: 03 Mar 2022
Toranomon Hospital - Department of Medical Oncology, affiliation not provided to SSRN, National Cancer Center Hospital East - Department of Breast and Medical Oncology, Kindai University - Department of Medical Oncology, Hokkaido University - Hokkaido University Hospital, Toranomon Hospital - Department of Medical Oncology, Toranomon Hospital - Department of Breast and Endocrine Surgery, Nagoya University - Graduate School of Medicine, Gifu University - Department of Surgical Oncology, Kobe University - Medical Oncology/Hematology, affiliation not provided to SSRN, Hiroshima University Hospital - Center for Integrated Medical Research, National Cancer Center Hospital - Department of Experimental Therapeutics and Toranomon Hospital - Department of Medical Oncology
Downloads 46 (1,109,210)

Abstract:

Loading...

Nivolumab, Bevacizumab, immunotherapy, VEGF, Metastatic breast cancer